Superbugs & Superdrugs USA
Renaissance Woodbridge Hotel, Iselin, New Jersey (November, 14 - 15, 2016)
Broadening horizons on the growing global threat of Antimicrobial resistance (AMR) for almost two decades at the sell-out Superbugs & Superdrugs conference in Europe, SMi is thrilled to announce the expansion of its antimicrobial portfolio of events across the Atlantic with the release of Superbugs & Superdrugs USA. This year’s show in Iselin, New Jersey, will play host to an audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to discuss the latest clinical advancements and funding opportunities.
With huge interest from leaders in the field including pending confirmations from PAHO/WHO, Astra Zeneca and other senior industry representatives, we have worked closely with an expert panel of speakers to present an agenda that is shaping up to be the best Superbugs & Superdrugs event to date.
The programme will hone in on key topics such as public private partnerships, collaboration, R&D, scientific priorities for antibiotic discovery, novel antibacterial therapeutic approaches, antibiotic stewardship, rapid diagnostic tools, combination therapies, resistance prevention, plus much more!
Featured speakers include:
• Dr Christopher Houchens, Branch Chief, Antibacterial's Program, BARDA
• Dr Rosemarie Aurigemma, Chief, Biodefense Drug Development Section , NIH
• Dr Anthony Simon Lynch, Senior Scientific Director, Janssen Research & Development LLC
• Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer
• Dr Alita Miller, Director of Biology, Entasis Therapeutics
• William J Weiss, Director, Pre-Clinical Services, UNT Health Science Center
• Dr Domingo Gargallo-Viola, Co-Founder and CSO, ABAC Therapeutics
• Dr David Cook, Chief Scientific Officer, Blueberry Therapeutics Ltd
Reasons to join:
• Network with industry-leading experts on drug and antimicrobial material developments
• Learn new funding opportunities from BARDA and US National plans, to combat antimicrobial resistance
• Strengthen your antibiotic pipeline with new insights on microbiome profiling to fight multi-resistant gram negative infections
• Hear important discussions on tackling major bottlenecks that hinder development of new antimicrobial drugs with our star panel line-up
• Discover novel protein-based biologics for the treatment and prevention of serious bacterial infections from Janssen
Attendee Testimonials From Our Recent Superbugs Show In London:
· “Great meeting to network and have time to discuss face to face. Key questions and issues. Very collaborative open meeting.” – Roche
· “It was one of the most useful scientific conferences that I have attended” – BARDA
· “Good mix of problems such as funding and novel opportunities and success stories” – TNO
· “I enjoyed attending the meeting this year and wanted to thank you for your efforts in organizing it” – UNT Health Science Centre
· “I like the mix of early stage technologies and also later stage products being presented” – Sempra Pharmaceuticals
Register early to take advantage of early bird savings at www.superbugs-usa.com/GATE2BIOTECH or contact Teri Arri on email: tarri@smi-online.co.uk, tel: +44 (0)20 7827 6162
